NCT00176813已完成2 期
Phase II Study of Gemcitabine, Cisplatin, and Celecoxib in the Treatment of Metastatic Pancreatic Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.
研究概览
简要总结
This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth.
This is a phase II clinical trial studying the reactions of the patient's body and their tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur. Blood levels of celecoxib will be measured to find out how this treatment affects factors (proteins) involved in new blood vessel formation and tumor growth (angiogenesis).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologic or cytologic diagnosis of pancreatic adenocarcinoma.
- •Patients must have clinical/radiologic evidence of metastatic disease (stage IV).
- •Patients must not have received prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed, provided that the last day of therapy was at least 6 months prior to starting treatment.
- •Patients must have performance status of 0-2 on the SWOG scale.
- •Patients must have an estimated life expectancy of at least 12 weeks.
- •Patients must have adequate bone marrow function: absolute neutrophil count >1,500/cmm, platelet count >100,000/cmm.
- •Patients must be informed of the investigational nature of this study and must give written informed consent prior to the receiving of treatment per this protocol.
- •Patients must practice effective birth control while receiving treatment.
排除标准
- •Patients with endocrine tumors or lymphoma of the pancreas.
- •Patients with locally advanced pancreatic cancer.
- •Patients with a proven history (radiographic and/or endoscopic) of peptic ulcer or esophageal erosions within one year of enrollment onto the study.
- •Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs.
- •History of active central nervous system (CNS) metastases.
- •Inadequate liver function (bilirubin >3.0 mg/dL); transaminases (AST/ALT) >3 times upper limit of institutional normal.
- •Inadequate renal function (creatinine >1.5 mg/dL).
- •Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- •History of other malignancy, except for cancers that have been treated with a curative intent and patient is without evidence of active disease.
- •Unresolved bacterial infection requiring treatment with antibiotics.
- •Pregnant or lactating women may not participate in the study.
- •Patients who have allergy to any of the study drugs or sulfa drugs.
- •Patients infected with HIV-1 virus because of the undetermined effect of this chemotherapy regimen in patients with HIV-1 and the potential for serious interaction with anti-HIV medications.
结局指标
主要结局
To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.
时间窗: 12 months
次要结局
- To obtain data on overall time to disease progression(12 months)
- To determine time to treatment failure(12 months)
- To determine the tolerability of celecoxib with gemcitabine and cisplatin.(12 months)
- To characterize the nature of the toxicity for this combination in this patient group.(12 months)
- To determine objective tumor response(12 months)
- To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis(12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary CancersStage III Intrahepatic Cholangiocarcinoma AJCC v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IVA Gallbladder Cancer AJCC v7Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7Stage IVB Gallbladder Cancer AJCC v7Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7Unresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder CarcinomaNCT02392637M.D. Anderson Cancer Center62
已完成
2 期
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBCMetastatic Breast CancerNCT00601159Fudan University70
进行中（未招募）
2 期
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic AlterationsInfiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial CarcinomaNCT03609216Alliance for Clinical Trials in Oncology237
招募中
2 期
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06298968Nanfang Hospital, Southern Medical University38
招募中
2 期
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerGallbladder Cancer UnresectableNCT06591650Fudan University33